Death in Chinese gene-editing trial exposes ethical fault linesThe death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how regulators should oversee first-in-human personalized gene therapies.